Lazard Asset Management’s Esperion Therapeutics ESPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-43,815
| Closed | -$63K | – | 2363 |
|
|
2025
Q1 | $63K | Buy |
43,815
+31,464
| +255% | +$45.2K | ﹤0.01% | 1942 |
|
|
2024
Q4 | $27K | Hold |
12,351
| – | – | ﹤0.01% | 2050 |
|
|
2024
Q3 | $20K | Buy |
12,351
+657
| +6% | +$1.06K | ﹤0.01% | 1999 |
|
|
2024
Q2 | $25K | Buy |
+11,694
| New | +$25K | ﹤0.01% | 2004 |
|
|
2023
Q1 | – | Sell |
-145,953
| Closed | -$909K | – | 2375 |
|
|
2022
Q4 | $909K | Buy |
145,953
+62,385
| +75% | +$389K | ﹤0.01% | 1014 |
|
|
2022
Q3 | $559K | Buy |
83,568
+51,176
| +158% | +$342K | ﹤0.01% | 1080 |
|
|
2022
Q2 | $206K | Sell |
32,392
-24,035
| -43% | -$153K | ﹤0.01% | 1276 |
|
|
2022
Q1 | $261K | Buy |
56,427
+20,136
| +55% | +$93.1K | ﹤0.01% | 1211 |
|
|
2021
Q4 | $181K | Sell |
36,291
-133,109
| -79% | -$664K | ﹤0.01% | 1297 |
|
|
2021
Q3 | $2.04M | Buy |
169,400
+142,400
| +527% | +$1.72M | ﹤0.01% | 911 |
|
|
2021
Q2 | $571K | Buy |
+27,000
| New | +$571K | ﹤0.01% | 1039 |
|
|
2018
Q2 | – | Sell |
-12,106
| Closed | -$875K | – | 1053 |
|
|
2018
Q1 | $875K | Buy |
+12,106
| New | +$875K | ﹤0.01% | 725 |
|
|
2015
Q3 | – | Sell |
-1,450
| Closed | -$118K | – | 1099 |
|
|
2015
Q2 | $118K | Sell |
1,450
-24,795
| -94% | -$2.02M | ﹤0.01% | 897 |
|
|
2015
Q1 | $2.43M | Buy |
26,245
+26,045
| +13,023% | +$2.41M | 0.01% | 617 |
|
|
2014
Q4 | $8K | Buy |
+200
| New | +$8K | ﹤0.01% | 1089 |
|